17864-NANAPs showed a 40-fold higher binding to EGFR-positive squamous head and neck cancer cells leading to the successful release in the tumour cell and inhibition of proliferation; in contrast, the non-targeted formulations had no antiproliferative effects on HNSCC cells [564]. This evidence concerns the gene EGFR and neoplasm.